It's best to follow the SEC filings. Look at AHIX, last

New Post Public Reply Private Reply Replies (1) Message Board
joey68 Fasstcat #599
It's best to follow the SEC filings. Look at AHIX, last week it had one billion in volume, and now its back to its usual self. High volume by itself doesn't mean anything. If SPCL is going to move, itll move on its own when its ready.

Solaris Power Cells, Inc (SPCL) Stock Research Links

SPCL Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 77

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Beverly Hills Body Academy: A New Era in Contouring

Updated Category News Views 93

Setting New Standards in Body Contouring It's no secret that Beverly Hills is all about luxury and cutting-edge trends. So, when the Beverly Hills Body Academy™ (BHBA) sets up shop in this glitzy locale, it's a pretty loud statement in the world of body contouring. This isn't just another vanity-driven operation; it's about pioneering advancements in the field of body...

Continue Reading
Future FinTech Under Investigation: Shareholder Impact Looms

Updated Category News Views 81

Future FinTech Faces Legal Scrutiny When the walls close in under financial suspicion, the spotlight can burn brighter than any anticipated market gain. That's precisely what Future FinTech Group Inc. (NasdaqCM: FTFT) is up against now. Kahn Swick & Foti, LLC, featuring the ex-Attorney General of Louisiana, Charles C. Foti, Jr., has begun scrutinizing the actions of...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 157

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 94

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Nemazee Fellowship Advances Clemency and Justice Reform

Updated Category News Views 96

Nemazee Fellowship: A Catalyst for Change You're probably wondering what's really happening when a couple like Hassan and Nazie Nemazee put their name on a legal fellowship. Skipping the melodrama, it's all about making a dent in the criminal justice system. These two aren't just slapping their name on a plaque—they're throwing real support behind actions that matter....

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 77

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
Blue Owl Tech Faces Lawsuit Post-44% Share Dive

Updated Category News Views 59

The air's thick with tension for investors of Blue Owl Technology Finance Corp. (NYSE:OTF) as they wake up to the news of a securities class action lawsuit that's no small fry. You don’t have to look too far to see why the folks holding the bag might be steamed. We’re talking about a 44% drop in stock price since the merger with Blue Owl Technology Finance Corp....

Continue Reading
AXON Revenue Forecast Cut Spurs Legal Investigation

Updated Category News Views 135

Axon's Revenue Forecast Takes a Hit Listen up, folks. Axon Enterprise, Inc. (NASDAQ: AXON) has stirred the pot, cutting their 2026 revenue forecast faster than you can say "counter-drone deployment." Back in August, they were riding high on their second-quarter call, raising their growth forecast to a cheerful 32%-34%. Fast forward to November, and it's been slashed to...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 204

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading

Top 5 Most Recently Viewed Articles

SoFi Technologies Reports Strong Growth and Raises Outlook

Updated Category News Views 233

Impressive Q3 Performance for SoFi Technologies SoFi Technologies Inc (NASDAQ: SOFI) released its third-quarter financial results that exceeded market expectations, illustrating impressive growth across multiple metrics. Initially, the shares rose following this announcement, although they experienced a slight pullback later. This article explores the key highlights from...

Continue Reading
JD.com Leverages AI Innovations Amid Market Fluctuations

Updated Category News Views 230

JD.com Integrates AI and Robotics for Enhanced Efficiency JD.com Inc. has showcased a strong commitment to using cutting-edge technology to automate its operations. The Chinese e-commerce giant, known for its innovative spirit, has reported impressive fourth-quarter results, demonstrating growth despite recent market fluctuations. Nonetheless, shares listed in Hong Kong...

Continue Reading
PhotonPharma Welcomes Derek Brown as New CEO for Growth

Updated Category News Views 194

PhotonPharma Appoints New CEO Derek Brown PhotonPharma Inc., a pioneering company focused on autologous cancer immunotherapies, has recently appointed Derek Brown as its new Chief Executive Officer. This development marks an exciting chapter for the company as it strives to push forward in the realms of innovative cancer treatments. Derek steps into this crucial role with...

Continue Reading
ParaZero Technologies Secures $3.1 Million Funding for Growth

Updated Category News Views 149

ParaZero Technologies Closes Successful Funding Round ParaZero Technologies Ltd. (NASDAQ: PRZO), a prominent aerospace company dedicated to developing safety systems for unmanned aircraft and defense counter-drone technologies, has exciting news. The company has successfully completed a registered direct offering, securing approximately $3.1 million in funds from...

Continue Reading
Costco's Remarkable Quarter: Growth Fueled by Loyalty and Traffic

Updated Category News Views 95

Costco's Impressive Financial Performance Shares of Costco Wholesale Corp (NASDAQ: COST) have shown volatility in early trading recently, following the company's announcement of upbeat fiscal first-quarter results. Analysts remain optimistic about the company's performance, highlighting strong growth driven by customer loyalty and store traffic. Key Takeaways from...

Continue Reading